Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

IV Cocaine Abuse: A Laboratory Model - 2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00000213
Recruitment Status : Completed
First Posted : September 21, 1999
Last Update Posted : August 28, 2015
Sponsor:
Collaborators:
National Institute on Drug Abuse (NIDA)
Columbia University
Information provided by (Responsible Party):
New York State Psychiatric Institute

Brief Summary:
The purpose of this study is to evaluate the effects of fluoxetine maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving.

Condition or disease Intervention/treatment Phase
Cocaine-Related Disorders Drug: Fluoxetine Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 0 participants
Primary Purpose: Treatment
Official Title: IV Cocaine Abuse: A Laboratory Model
Study Start Date : April 1990
Actual Primary Completion Date : April 1991
Actual Study Completion Date : April 1991

Resource links provided by the National Library of Medicine

Drug Information available for: Fluoxetine




Primary Outcome Measures :
  1. Direct cocaine effects
  2. Interaction of cocaine/fluox. on cardio measures
  3. Interaction of cocaine/fluox. on coc's subjective
  4. Effects of fluoxetine on cocaine craving
  5. Drug use during outpatient fluoxetine maintenance


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000213


Locations
Layout table for location information
United States, New York
Columbia University
New York, New York, United States, 10023
Sponsors and Collaborators
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)
Columbia University
Investigators
Layout table for investigator information
Principal Investigator: Richard Foltin, Ph.D. Columbia University
Layout table for additonal information
Responsible Party: New York State Psychiatric Institute
ClinicalTrials.gov Identifier: NCT00000213    
Other Study ID Numbers: NIDA-06234-2
R01DA006234 ( U.S. NIH Grant/Contract )
R01-06234-2
First Posted: September 21, 1999    Key Record Dates
Last Update Posted: August 28, 2015
Last Verified: December 2012
Keywords provided by New York State Psychiatric Institute:
intravenous abuse
Additional relevant MeSH terms:
Layout table for MeSH terms
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Fluoxetine
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors